For more than two decades, the debate of menopause hormone therapy evolved around a simple yes-or-no question: safe or dangerous? That oversimplified view has let women down.
In November 2025, the U.S. Food and Drug Administration removed the black-box label from low-dose vaginal estrogen and softened language on systemic therapy. It happened quietly but signals something important: Hormone therapy was never meant to be one-size-fits-all.
